Key points
- A mass spectrometer has three core parts: an ion source that gives molecules an electric charge, a mass analyzer that sorts them, and a detector that counts them.
- Molecules are sorted by their mass-to-charge ratio (m/z), which reveals what they are and, with calibration, how much is present.
- Soft ionization methods that let large biological molecules be analyzed intact earned John Fenn and Koichi Tanaka a share of the 2002 Nobel Prize in Chemistry.
- Liquid or gas chromatography is usually paired with mass spectrometry to separate complex mixtures first.
- In drug development, mass spectrometry measures drug concentrations in blood for pharmacokinetic studies, and identifies proteins in proteomics.
Mass spectrometry is one of the most widely used measurement techniques in biomedical science. It can identify an unknown molecule, measure tiny amounts of a drug in a blood sample, or catalog thousands of proteins in a tissue. All of this rests on a simple idea: weigh molecules very precisely.
The basic principle
A mass spectrometer measures the mass-to-charge ratio (m/z) of charged particles called ions. Because molecules of different structures have different masses, a precise measurement of m/z reveals what a molecule is. Measuring how many ions arrive at each m/z value, compared against known standards, shows how much of each molecule is present.
The output is a mass spectrum: a chart with m/z along one axis and signal intensity along the other. Each peak corresponds to ions of a particular m/z.
The three core components
| Component | What it does | Common types |
|---|---|---|
| Ion source | Converts molecules into charged ions in the gas phase | Electrospray ionization (ESI), matrix-assisted laser desorption/ionization (MALDI) |
| Mass analyzer | Separates ions according to their m/z | Quadrupole, time-of-flight (TOF), ion trap, Orbitrap |
| Detector | Counts the ions arriving at each m/z | Electron multipliers and related detectors |
1. Ionization
Molecules must carry an electric charge before the instrument can move and sort them. Large biological molecules, such as proteins, used to be very difficult to ionize without breaking them apart. Two "soft" ionization methods solved this:
- Electrospray ionization (ESI) sprays a liquid sample through a charged needle, producing a fine mist of charged droplets that evaporate to leave charged molecules.
- Matrix-assisted laser desorption/ionization (MALDI) mixes the sample with a matrix material and uses a laser pulse to lift and ionize the molecules.
John Fenn and Koichi Tanaka shared half of the 2002 Nobel Prize in Chemistry for developing soft desorption ionization methods for mass spectrometric analyses of biological macromolecules.
2. Mass analysis
Once ionized, molecules are sorted by m/z using electric or magnetic fields. For example, in a time-of-flight analyzer, ions are given the same energy and race down a tube. Lighter ions arrive first. In a quadrupole, oscillating electric fields let only ions of a chosen m/z pass through.
3. Detection
The detector records how many ions arrive at each m/z, producing the mass spectrum.
Tandem mass spectrometry
In tandem mass spectrometry (MS/MS), a chosen ion is selected, broken into fragments, and the fragments are measured in a second stage. The fragment pattern works like a fingerprint. It confirms a molecule's identity and, for peptides, reveals the order of amino acids. MS/MS is the workhorse of both protein identification and precise drug measurement.
Separating mixtures first
Biological samples contain thousands of molecules. To keep them from overwhelming the instrument at once, mass spectrometry is usually coupled to a separation step:
- Liquid chromatography (LC-MS), which separates molecules dissolved in liquid as they pass through a column, and
- Gas chromatography (GC-MS), used for molecules that can be vaporized.
Molecules leave the column at different times and enter the mass spectrometer one group at a time.
How mass spectrometry is used in drug development
Measuring drug levels
To understand how the body absorbs, distributes, and clears a drug, its pharmacokinetics, researchers measure drug concentrations in blood and other samples over time. LC-MS/MS is the standard tool for small-molecule drugs. The International Council for Harmonisation's M10 guideline on bioanalytical method validation covers these measurements in nonclinical studies and all phases of clinical trials. It notes that chromatographic methods are typically used with mass spectrometry detection.
Finding drug metabolites
The body chemically transforms many drugs into metabolites. Mass spectrometry identifies them and measures their levels, which matters for both effectiveness and safety.
Proteomics
Mass spectrometry is a core technology of proteomics, the large-scale study of proteins. Proteins are cut into peptides, measured by LC-MS/MS, and identified by matching the spectra against protein sequence databases. This helps researchers discover drug targets and biomarkers. That matters because most drugs act on proteins: one analysis identified 667 human proteins targeted by FDA-approved drugs.
Characterizing biologic drugs
For protein-based medicines such as monoclonal antibodies, mass spectrometry confirms the molecule's structure, checks its chemical modifications, and helps show that manufacturing batches are consistent.
Strengths and limitations
| Strengths | Limitations |
|---|---|
| Very high specificity and sensitivity | Expensive instruments that require skilled operators |
| Can measure many molecules in one run | Signals can be suppressed by other substances in the sample |
| Identifies unknown molecules | Accurate quantification requires careful calibration and standards |
| Detects chemical modifications | Very low-abundance proteins in blood remain hard to measure |
For measuring very large numbers of proteins in population studies, researchers often complement mass spectrometry with affinity-based methods, which use antibodies or similar binding molecules. The UK Biobank Pharma Proteomics Project, for example, measured 2,923 plasma proteins across 54,219 participants using an affinity-based platform.
Sources
- The Nobel Prize in Chemistry 2002: press release.Industry report
- International Council for Harmonisation. M10: Bioanalytical Method Validation and Study Sample Analysis (2022).Regulator
- Santos R, et al. A comprehensive map of molecular drug targets. Nature Reviews Drug Discovery. 2017;16(1):19–34.Peer-reviewed
- Sun BB, et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature. 2023;622:329–338.Peer-reviewed
- The Human Protein Atlas.Registry
This article is for education. It is not medical advice and not investment advice. Figures are drawn from the sources above and describe historical averages, not the prospects of any particular drug. See our editorial standards and disclaimer.